A multi-center male birth control pill study co-sponsored by the UN and WHO reported that male participants quit because of mood swings.

The cumulative reversibility of suppression of spermatogenesis after 52 weeks of recovery was 94.8 per 100 continuing users (95% CI, 91.5–97.1). The most common adverse events were acne, injection site pain, increased libido, and mood disorders. Following the recommendation of an external safety review committee the recruitment and hormone injections were terminated early.

The study concluded that the regimen led to near-complete and reversible suppression of spermatogenesis. The contraceptive efficacy was relatively good compared with other reversible methods available for men. The frequencies of mild to moderate mood disorders were relatively high.

The clinical study was cosponsored and funded by United Nations Development Programme/United Nations Population Fund/United Nations International Children’s Emergency Fund/ World Health Organization/World Bank Special Programme of Research, Development, and Research Training in Human Reproduction (Human Reproduction Progamme, World Health Organization, Geneva, Switzerland) and CONRAD (Eastern Virginia Medical School, Arlington, VA using funding from the Bill & Melinda Gates Foundation and U.S. Agency for International Development).